
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is poised for success due to their strong pipeline and upcoming catalysts which include dose escalation results from Phase 1b trials evaluating their advanced programs targeting Nectin-4 and B7H3, clinical imaging and dosimetry assessment of AKY-2519, and commencement of IND-enabling studies for two earlier stage programs. While there are risks, such as negative clinical results and delays in advancing pipeline candidates, the company's market value of $1.93B and 12-month price target of $35 per share showcase its potential for significant growth.
Bears say
Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for a broad range of solid tumors, with a pipeline consisting of products such as AKY-1189 and AKY-2519. Despite positive imaging and dosimetry results for AKY-2519, negative financial results reported for 2025 and projected for 2026, including a net loss of $78.34 per share and R&D expenses of $67.5M, raise concerns about the company's ability to successfully advance its pipeline and obtain regulatory approvals in a timely manner. Additionally, competition in the RIT/RLT space and potential long-term dilution risk are significant risks for investors to consider.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares